The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to
at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance
capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the
overall treatment success rate of MDR-TB is 55% while much lower in China at just only 41%
with the 24-month regimen. In order to further verify the safety and efficiency of optimizing
shorter 18-month regimen containing 6 anti-TB drugs with MDR-TB patients,500 more patients
will be enrolled and observed.